Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Arribillaga, L. (Laura) | - |
dc.creator | Dotor, J. (Javier) | - |
dc.creator | Basagoiti, M. (María) | - |
dc.creator | Riezu-Boj, J.I. (José Ignacio) | - |
dc.creator | Borras-Cuesta, F. (Francisco) | - |
dc.creator | Lasarte, J.J. (Juan José) | - |
dc.creator | Sarobe, P. (Pablo) | - |
dc.creator | Cornet, M.E. (María Eugenia) | - |
dc.creator | Feijoo, E. (Esperanza) | - |
dc.date.accessioned | 2012-04-04T07:19:07Z | - |
dc.date.available | 2012-04-04T07:19:07Z | - |
dc.date.issued | 2011 | - |
dc.identifier.citation | Arribillaga L, Dotor J, Basagoiti M, Riezu-Boj JI, Borras-Cuesta F, Lasarte JJ, et al. Therapeutic effect of a peptide inhibitor of TGF-beta on pulmonary fibrosis. Cytokine 2011 Mar;53(3):327-333. | es_ES |
dc.identifier.issn | 1096-0023 | - |
dc.identifier.uri | https://hdl.handle.net/10171/21580 | - |
dc.description.abstract | Pulmonary fibrosis encompasses several respiratory diseases characterized by epithelial cell injury, inflammation and fibrosis. Transforming growth factor (TGF)-β1 is one of the main profibrogenic cytokines involved in the pathogenesis of lung fibrosis. It induces fibroblast differentiation into myofibroblasts, which produce high levels of collagen and concomitantly loss of lung elasticity and reduction of the respiratory function. In the present study, we have investigated the effects of P17 (a TGF-β inhibitor peptide) on IMR-90 lung fibroblast differentiation in vitro, as well as on the inhibition of the development of bleomycin-induced pulmonary fibrosis in mice. It was found that in IMR-90 cells, P17 inhibited TGF-β1-induced expression of connective tissue growth factor and α-smooth muscle actin. In vivo, treatment of mice with P17 2days after bleomycin administration decreased lung fibrosis, areas of myofibroblast-like cells and lymphocyte infiltrate. P17 also reduced mRNA expression of collagen type I, fibronectin and the fibronectin splice isoform EDA in the lung, and increased the expression of IFN-γ mRNA. Finally, therapeutic treatment with P17 in mice with already established fibrosis was able to significantly attenuate the progression of lung fibrosis. These results suggest that P17 may be useful in the treatment of pulmonary fibrosis. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | info:eu-repo/semantics/closedAccess | - |
dc.subject | Myofibroblasts | es_ES |
dc.subject | Peptide | es_ES |
dc.subject | Pulmonary fibrosis | es_ES |
dc.subject | Transforming growth factor-β1 | es_ES |
dc.title | Therapeutic effect of a peptide inhibitor of TGF-β on pulmonary fibrosis | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | http://www.sciencedirect.com/science/article/pii/S1043466610007696 | es_ES |
dc.type.driver | info:eu-repo/semantics/article | es_ES |
Files in This Item:
There are no files associated with this item.
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.